Aminohippuric acid

Aminohippuric acid: Overview

Aminohippuric acid is a diagnostic agent used in nephrology to evaluate kidney clearance and tubular excretory capacity. It is administered parenterally as an intravenous injection or continuous infusion to measure effective renal plasma flow and assess renal functional reserve.

What Is Aminohippuric acid & How Does It Work?

Aminohippuric acid, also known as para-aminohippuric acid or PAH, is a hippuric acid derivative in the aminobenzoate class. In renal physiology, measuring clearance of exogenous compounds allows assessment of renal plasma perfusion and tubular transport integrity.

Aminohippuric acid works through glomerular filtration and proximal tubular secretion. Intravenously injected Aminohippuric acid circulates in blood plasma. As blood flows through glomeruli, 20 percent is filtered into Bowman’s space. The remaining 80 percent enters peritubular capillaries, where organic anion transporters OAT1 and OAT3 transport Aminohippuric acid into proximal tubular cells. Apical transporters secrete it into the tubular lumen for excretion. At low plasma concentrations, a single pass through renal circulation results in 85 to 90 percent extraction, making its clearance an accurate measure of effective renal plasma flow. At high plasma concentrations, tubular secretion saturates, permitting measurement of total tubular secretory capacity.

Is Aminohippuric acid FDA Approved?

Aminohippuric acid received US FDA approval in December 1944 under the brand name Aminohippurate Sodium PAH, developed by Merck, as a sterile intravenous solution for diagnostic renal function testing.

The drug was produced as a 20 percent solution for intravenous injection. Commercial distribution was voluntarily discontinued in the United States as alternative imaging techniques and biomarker equations became preferred. The FDA listed Aminohippurate Sodium in the discontinued section of the Orange Book. Aminohippuric acid is classified as FDA Approved; withdrawn.

What Is Aminohippuric acid Used For?

• Estimation of effective renal plasma flow in research and nephrology evaluations (FDA Approved; historical use).
• Determination of renal tubular secretory capacity at saturating plasma concentrations (FDA Approved; historical use).
• Assessment of renal vascular resistance and blood flow changes in physiology studies (FDA Approved; historical use).
• Evaluation of renal parenchymal diseases and tubular transport defects (Unapproved; research use).

Before Taking Aminohippuric acid: Contraindications & Precautions

Evaluating allergy history, cardiac status, and renal failure severity is critical before administering Aminohippuric acid. Severe hypersensitivities strictly preclude administration.

Who Should Not Take Aminohippuric acid?

Aminohippuric acid is contraindicated in patients with severe hypersensitivity to Aminohippuric acid, sodium aminohippurate, or formulation excipients.

It is strictly contraindicated in patients with severe end-stage renal disease or anuria, as impaired excretion prevents accurate diagnostic interpretation and increases systemic accumulation risks.

Aminohippuric acid: Pregnancy & Fertility

Animal reproduction studies evaluating Aminohippuric acid have not been conducted. It is unknown whether Aminohippuric acid can cause fetal harm or affect reproductive capacity. Aminohippuric acid should be administered during pregnancy only when diagnostic necessity clearly outweighs potential fetal risks.

It is unknown whether Aminohippuric acid is excreted in human milk. Caution is advised when administering to nursing mothers. Effects on human fertility demonstrate no significant impairment in animal models.

Tell Your Doctor Before Taking Aminohippuric acid

Tell your physician if you have a history of allergies to para-aminobenzoic acid derivatives or sulfa drugs. Disclose any pre-existing heart failure or fluid overload.

Inform your doctor if you have chronic kidney disease, hepatic dysfunction, or dehydration. Disclose all concurrent medications, particularly probenecid.

Aminohippuric acid: Dosage & Administration

Proper administration and dosage of Aminohippuric acid depend on the specific diagnostic test protocol, whether measuring effective renal plasma flow or tubular transport capacity. Strict adherence to intravenous infusion rates ensures accurate diagnostic results.

Standard Aminohippuric acid Dosing

For adults measuring effective renal plasma flow, standard historical dosing involves a priming loading dose of 0.4 to 0.8 grams as a 20 percent solution, followed by continuous maintenance infusion of 10 to 15 milligrams per minute to maintain plasma concentrations around 2 milligrams per 100 mL.

For measuring maximal tubular secretory capacity, a higher priming dose is administered, followed by continuous maintenance infusion to maintain plasma concentrations above 30 to 50 milligrams per 100 mL, saturating tubular transport mechanisms.

How Aminohippuric acid Is Administered

Aminohippuric acid solution must be diluted in 5 percent dextrose or 0.9 percent sodium chloride prior to continuous infusion.

The priming dose is injected slowly, followed by continuous infusion. Timed urine collection and serial blood sampling are required throughout testing.

Aminohippuric acid: Clinical Efficacy & Research

Clinical research established that Aminohippuric acid clearance represents the gold standard for measuring effective renal plasma flow.

Research confirmed that proximal tubular cells extract 85 to 90 percent of arterial Aminohippuric acid in a single pass. Combining Aminohippuric acid clearance with inulin clearance allows calculation of filtration fraction, renal blood flow, and tubular secretory transport maximum.

Aminohippuric acid: Side Effects & Safety Profile

Clinical use of Aminohippuric acid requires monitoring for transient vasomotor reactions, infusion discomfort, and hypersensitivity events during diagnostic testing.

Common Aminohippuric acid Side Effects

• Vasomotor symptoms including transient facial flushing and warmth during priming injection.
• Gastrointestinal disturbances including mild nausea and altered taste.
• Localized injection site discomfort including mild phlebitis or warmth.
• Transient urge to urinate during initial loading infusion.

Serious Aminohippuric acid Adverse Events

• Severe acute hypersensitivity reactions, including anaphylaxis and facial angioedema.
• Acute fluid overload and pulmonary edema in patients with severe cardiac failure or renal impairment.
• Severe hypotension secondary to rapid intravenous injection.
• Interference with laboratory tests, including false elevations of urinary protein.

Managing Aminohippuric acid Side Effects

Infuse loading doses slowly over 3 to 5 minutes to minimize warmth and flushing. Ensure adequate hydration throughout testing.

If severe dyspnea, facial swelling, or hypotension occurs, discontinue infusion immediately and administer emergency supportive care.

Aminohippuric acid: Interactions & What to Avoid

Aminohippuric acid creates potential for diagnostic interference and pharmacological interactions when co-administered with drugs that compete for renal tubular transport proteins. Safe diagnostic testing requires screening concurrent medications.

Aminohippuric acid: Interactions

Co-administration of Aminohippuric acid with probenecid or salicylates inhibits OAT1 and OAT3 transport, reducing tubular secretion.

Co-administration with NSAIDs or penicillin derivatives can alter transport kinetics and elevate drug concentrations. Penicillin antibiotics compete for tubular secretion, altering test accuracy.

Aminohippuric acid: Food & Alcohol

Intravenous administration of Aminohippuric acid is not affected by meal timing, but patients should maintain adequate oral hydration prior to testing.

Alcohol consumption should be avoided prior to diagnostic testing. Alcohol induces systemic dehydration, alters renal hemodynamics, and compromises clearance measurement accuracy.

Aminohippuric acid: Missed Dose, Overdose & Storage

Consistent continuous infusion rates maintain steady diagnostic plasma concentrations. Clear protocols for handling interrupted infusions or acute toxicity ensure safety.

Missed Dose of Aminohippuric acid

Because Aminohippuric acid is administered as a single diagnostic procedure during controlled clinical testing, daily missed doses do not occur.

If an infusion is interrupted during testing, plasma concentrations fall rapidly, requiring re-equilibration with a fresh priming dose and continuous infusion before resuming urine collections.

Aminohippuric acid: Overdose & Emergency

Accidental overdose or rapid infusion of Aminohippuric acid can cause flushing, nausea, vomiting, dizziness, and fluid overload.

In case of overdose, discontinue infusion immediately. Treatment includes supportive care, IV fluids, and forced diuresis.

How to Store Aminohippuric acid

Store Aminohippuric acid solution at controlled room temperature between 15 degrees Celsius and 30 degrees Celsius.

Aminohippuric acid: Patient Management & Monitoring

Systematic patient preparation and serial blood and urine sampling optimize diagnostic test accuracy while safeguarding patient safety.

Tests Before Starting Aminohippuric acid

• Baseline serum creatinine, blood urea nitrogen, and estimated glomerular filtration rate.
• Baseline complete blood count and serum electrolytes.
• Verification of patient hydration status prior to infusion.

Monitoring During Aminohippuric acid Treatment

• Continuous monitoring of infusion rate and vital signs during testing.
• Timed collection and volume measurement of urine samples.
• Serial blood sampling for plasma Aminohippuric acid analysis.
• Observation for signs of phlebitis, flushing, or hypersensitivity reactions.

Aminohippuric acid: Do’s and Don’ts

• Do ensure complete emptying of the bladder at the start and end of timed urine collection.
• Do maintain steady infusion rates using an infusion pump.
• Don’t inject priming doses rapidly, as rapid injection induces flushing and nausea.
• Don’t administer Aminohippuric acid to patients taking probenecid without adjusting calculations.

Frequently Asked Questions

References

• Official FDA Labeling and Approval History: Aminohippurate Sodium (aminohippuric acid) Injection, Application No. NDA 005393.
• DrugBank Online: Aminohippuric acid (DB00345) Profile and Pharmacological Data.
• National Center for Biotechnology Information (NCBI) PubChem Summary: Aminohippuric Acid and Sodium Aminohippurate.

Legal Disclaimer

The information provided is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider at any hospital or clinic before starting or stopping any medication.